Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 26, Issue 4, Pages 471-485Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2012.09.008
Keywords
Hepatitis C virus; Direct acting antiviral agents; NS3/4A protease inhibitor; NS5A; NS5B; Nucleotide inhibitors; Non-nucleotide inhibitors; Cyclophilin inhibitor
Categories
Funding
- Roche
- Merck
- BI
- BMS
- Gilead
- Novartis
- Abbott
- Idenix
- National Institutes of Health Research (NIHR) [DRF-2010-03-29] Funding Source: National Institutes of Health Research (NIHR)
- National Institute for Health Research [DRF-2010-03-29] Funding Source: researchfish
Ask authors/readers for more resources
Treatment for those infected with chronic hepatitis C virus [HCV] has until recently been hampered by the lack of therapies other than pegylated interferon and ribavirin, which have limited efficacy and a difficult side effect profile. To address this, multiple new direct acting antiviral drugs which specifically target the nonstructural proteins involved in HCV replication are in phase II/III development. This review will discuss the HCV replication cycle, mechanisms of action of the new direct acting antiviral drugs, results from published trials into their efficacy and the potential for interferon free treatment regimens in the future. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available